CryoPort Inc (CYRX)

[H2R]

582 clinical trials and 8 commercial therapies in regenerative medicine

Note: In August 2021: a record 561 clinical trials, compared with 543 at the end of the first quarter of 2021 and 491 at the end of the second quarter of 2020



Earnings Report Nov. 4th, 2021 highlights:

- Third quarter revenue increased 407% year over year, reaching $56.7 million; Nine Months 2021 revenue $166.2 million

- Organic Revenue Growth of 38% coupled with continuing strong performance by MVE Biological Solutions and CRYOPDP

- Now supporting a record 582 clinical trials and eight commercial therapies in regenerative medicine

Net loss attributable to common stockholders was $8.5 million, or $0.18 per share, for the third quarter of 2021, compared to a net loss attributable to common stockholders of $11.4 million, or $0.29 per share, for the third quarter of 2020.

This loss reflects a paid-in-kind dividend of $2.0 million and $6.2 million during the third quarter and nine months ended September 30, 2021, respectively, resulting from the private placement of Series C Preferred Stock with the Blackstone Group, completed in connection with the MVE Biological Solutions acquisition.

CYRX keeps building a juggernaut growth engine.

Full details:
http://ir.cryoport.com/news-releases/2021/11-04-2021-201106440